A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (NCT04629248)

🧪 Interventions in This Study

• Obinutuzumab (DRUG)
• Tacrolimus (DRUG)
• Methylprednisolone (DRUG)
• Acetaminophen (DRUG)
• Diphenhydramine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (50 Sites)

Showing the first 25 of 50 sites.

• Kaiser Permanente - San Francisco Medical Center — San Francisco, California
• University of Colorado in Denver-Anschutz Medical Campus — Aurora, Colorado
• Accel Research Sites; Mid-Florida Kidney and Hypertension Care — Altamonte Springs, Florida
• University of Iowa — Iowa City, Iowa
• Henry Ford Hospital — Detroit, Michigan
• Mayo Clinic — Rochester, Minnesota
• Columbia University Medical Center — New York, New York
• Nephrotex Research Group — Dallas, Texas
• Organizacion Medica de Investigacion — Buenos Aires,
• CINME — Buenos Aires,
• Hospital Britanico Buenos Aires — Buenos Aires,
• Ser Servicos Especializados Em Reumatologia — Salvador, Estado de Bahia
• Hospital de Base de Sao Jose do Rio Preto — São José do Rio Preto, São Paulo
• Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos — São Paulo, São Paulo
• Hospital das Clinicas - FMUSP — São Paulo, São Paulo
• Zhejiang Provincial People?s Hospital — Hangzhou, Zhejiang
• Peking University First Hospital — Beijing,
• Sichuan Provincial People's Hospital — Chengdu,
• The 1st Affiliated hospital of Fujian Medical University — Fuzhou,
• Nanfang Hospital, Southern Medical University — Guangzhou,
• Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai,
• Huashan Hospital, Fudan University — Shanghai,
• Tongji Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan,
• The First Affiliated Hospital of Xian Jiao Tong University — Xi'an,
• General Hospital of Ningxia Medical University — Yinchuan,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Membranous Nephropathy

• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Granada Hills, California
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Montgomery, Alabama
• Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Loma Linda, California
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Huntsville, Alabama
• A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy — Denver, Colorado

Explore by condition: All Primary Membranous Nephropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.